Skip to Content
Is technology key to beating breast cancer? Learn more >

Vinblastine Pregnancy and Breastfeeding Warnings

Vinblastine is also known as: Velban

Vinblastine Pregnancy Warnings

When administered as a part of combination antineoplastic therapy, vinblastine may produce gonadal dysfunction in men and women. Following first trimester exposure to vinblastine in combination with other chemotherapeutic agents, two cases of malformed infants have been reported. The first case was spontaneously aborted with oligodactyly of both feet and webbing of the third and fourth toes, which was attributed to mechlorethamine therapy. In the second case, the newborn developed fatal respiratory distress syndrome and autopsy showed a small secundum atrial septal defect.

Vinblastine has been assigned to pregnancy category D by the FDA. Animal studies have revealed evidence of teratogenicity. There are no controlled data in human pregnancy. Aspermia has been reported in males. Vinblastine should only be given during pregnancy when there are no safer alternatives and benefit outweighs risk. If this drug is used during pregnancy, or if the patient becomes pregnant while receiving this drug, she should be apprised of the potential hazard to the fetus. Women of childbearing potential should be advised to avoid becoming pregnant while receiving this medication.

See references

Vinblastine Breastfeeding Warnings

There are no data on the excretion of vinblastine into human milk. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions to vinblastine in nursing infants, a decision should be made whether to discontinue nursing or the drug, taking into account the importance of the drug to the mother.

See references

References for pregnancy information

  1. "Product Information. Velban (vinblastine)." Lilly, Eli and Company, Indianapolis, IN.
  2. Briggs GG, Freeman RK, Yaffe SJ.. "Drugs in Pregnancy and Lactation. 5th ed." Baltimore, MD: Williams & Wilkins (1998):

References for breastfeeding information

  1. "Product Information. Velban (vinblastine)." Lilly, Eli and Company, Indianapolis, IN.
  2. Briggs GG, Freeman RK, Yaffe SJ.. "Drugs in Pregnancy and Lactation. 5th ed." Baltimore, MD: Williams & Wilkins (1998):

See Also...

Disclaimer: Every effort has been made to ensure that the information provided by Cerner Multum, Wolters Kluwer Health and Drugs.com is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. This drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2008 Multum Information Services, Inc. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.

Hide